收藏切换
Advances in N-acetylgalactosamine and its derivatives as delivery vehicles of small interfering RNA and antisense oligonucleotides
收藏切换
PDF
Da-wei LI1, 2, 3, Kai-fan MAO1, 3, Xue-hua YANG1, 3, Song XUE1, 3, Zheng-ping LIU1, 3
Chinese Journal of New Drugs | 2023, 32(13) : 1336 - 1344
Less
收藏切换
Chinese Journal of New Drugs | 2023, 32(13): 1336-1344
Advances in N-acetylgalactosamine and its derivatives as delivery vehicles of small interfering RNA and antisense oligonucleotides
Full
Da-wei LI1, 2, 3, Kai-fan MAO1, 3, Xue-hua YANG1, 3, Song XUE1, 3, Zheng-ping LIU1, 3
Affiliations
  • 1Shandong Academy of Pharmaceutical Sciences, Jinan 250101, China
  • 2NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, Jinan 250101, China
  • 3Shandong Provincial Key Laboratory of Mucosal and Skin Drug Delivery Technology, Jinan 250101, China
Published: 2023-07-15
Outline
收藏切换

In recent years, the use of N-acetylgalactosamine (GalNAc) conjugates to target asialoglycoprotein receptors and further deliver oligonucleotides to hepatocytes has become a breakthrough approach in the field of therapeutic oligonucleotides. Compared with traditional delivery methods of nucleic acid drugs, GalNAc-nucleic acid conjugation is a simple method of liver delivery. It exhibits liver targeting specificity, high efficiency, high safety, large-scale preparation and many other advantages, thus has research value of in-depth development and broad prospects for clinical application. Givosiran, developed using GalNAc conjugation, has been approved by FDA for the treatment of acute hepatic porphyria, and there are 7 other conjugates are in registration review or phase III clinical trials, and at least 21 GalNAc nucleic acid conjugates are in the early stages of clinical development. However, the relevant research foundation of GalNAc conjugation in China is relatively weak, and no related products are on the market, making it a neck-stuck technology in China. Therefore, this review focuses on GalNAc and its derivatives as nucleic acid drug delivery vehicles and their application progress in small interfering RNA (siRNA) and antisense oligonucleotides (ASO). This review provides reference for the development of domestic GalNAc conjugates.

N-acetylgalactosamine  /  small interfering RNA  /  antisense oligonucleotides  /  preclinical research  /  clinical research  /  listing
Da-wei LI, Kai-fan MAO, Xue-hua YANG, Song XUE, Zheng-ping LIU. Advances in N-acetylgalactosamine and its derivatives as delivery vehicles of small interfering RNA and antisense oligonucleotides[J]. Chinese Journal of New Drugs, 2023 , 32 (13) : 1336 -1344 .
Year 2023 volume 32 Issue 13
PDF
49
13
Cite this Article
BibTeX
Article Info
  • Online Date:2026-03-05
  • Published:2023-07-15
Article Data
Affiliations
History
  • Accepted:2022-09-26
Funding
Affiliations
    1Shandong Academy of Pharmaceutical Sciences, Jinan 250101, China
    2NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, Jinan 250101, China
    3Shandong Provincial Key Laboratory of Mucosal and Skin Drug Delivery Technology, Jinan 250101, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT